Evidence map›Paper›PMID 41153450›Full record

ArticleGenes2025

CRISPR/Cas Tools for the Detection of

Ermanno Nardon, Eros Azzalini, Dino Paladin, Diego Boscarino, Serena Bonin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ermanno NardonDepartment of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.
Eros AzzaliniDepartment of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.ORCID 0000-0002-5193-268X
Dino PaladinAB Analitica S.r.l., 35127 Padova, Italy.
Diego BoscarinoAB Analitica S.r.l., 35127 Padova, Italy.ORCID 0009-0003-5774-1723
Serena BoninDepartment of Medical Sciences (DSM), University of Trieste, 34149 Trieste, Italy.ORCID 0000-0002-7349-0296

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesLyme disease diagnosis remains challenging due to the limitations of current methods. While PCR-based assays are widely used, their sensitivity can be affected by sample type and the inhibition of host DNA. This study aimed to evaluate the feasibility and sensitivity of a CRISPR/Cas12-based detection system for

methodsDNA from three

resultsDirect detection of

conclusionsThe Cas12/crRNA-based system offers a sensitive and accessible alternative to qPCR, especially in settings lacking real-time PCR instrumentation. Future developments may include integration with isothermal amplification and microfluidic platforms to enhance direct detection capabilities.

Indexed as

Borrelia burgdorferi GroupCRISPR-Cas SystemsLyme DiseaseAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesDNA, BacterialHumansLipoproteinsReal-Time Polymerase Chain ReactionSensitivity and SpecificityAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesDNA, BacterialLipoproteinsOspA proteinBorreliaCas12detectionLyme diseasePCR

Identifiers

PMID41153450
PMCPMC12564912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.